Zosurabalpin: a potential super antibiotic against a super bacteria
Keywords:
Acinetobacter baumannii, zosurabalpin, antibioticAbstract
The use of antibiotics since the discovery of penicillin has been one of the most important medical advances in humanity. However, bacteria have developed strategies to evade them, becoming “super bacteria” resistant to them. Among them is Acinetobacter
baumannii, an opportunistic microorganism considered of critical priority for public health. From a pessimistic point of view, we are losing the battle against super bacteria like A. baumannii; however, recently, a group of scientists has developed a new antibiotic to combat it, zosurabalpin. What is known about the potential and novel super antibiotic? Let’s find out together.
References
Bentley, R., & Bennett, J. W. (2003). What is an antibiotic? Revisited. Advances in Applied Microbiology, 52, 303-332. https://doi.org/10.1016/S0065-2164(03)01012-8
Zaffiri, L., Gardner, J., Toledo-Pereyra, L. H. (2012). History of antibiotics. From salvarsan to cephalosporins. Journal of Investigative Surgery, 25(2), 67-77. https://doi.org/10.3109/08941939.2012.664099
Calvo, J., & Martinez-Martinez, L. (2009). Antimicrobial mechanisms of action. Enfermedades infecciosas y microbiologia clinica, 27(1), 44-52. https://doi.org/10.1016/j.eimc.2008.11.001
Aminov, R. I. (2010). A brief history of the antibiotic era: lessons learned and challenges for the future. Frontiers in Microbiology, 1, 134. https://doi.org/10.3389/fmicb.2010.00134
Oliveira, J., & Reygaert, W. C. (2023). Gram-Negative Bacteria. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538213/
Nguyen, M., Joshi, S. G. (2021). Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review. Journal of Applied Microbiology, 131(6), 2715-2738. https://doi.org/10.1111/jam.15130
Havenga, B., Ndlovu, T., Clements, T., Reyneke, B., Waso, M., & Khan, W. (2019). Exploring the antimicrobial resistance profiles of WHO critical priority list bacterial strains. BMC Microbiology, 19, 1-16. https://doi.org/10.1186/s12866-019-1687-0
Pahil, K. S., Gilman, M. S. A., Baidin, V., Clairfeuille, T., Mattei, P., Bieniossek, C., Dey, F., Kahne, D. (2024). A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature, 1-6. https://doi.org/10.1038/s41586-023-06799-7
Zampaloni, C., Mattei, P., Bleicher, K., Winther, L., Thäte, C., Bucher, C., Adam, J. M., Alanine, A., Amrein, K. E., Baidin, V., Bieniossek, C., Bissantz, C., Boess, F., Cantrill, C., Clairfeuille, T., Dey, F., Di Giorgio, P., du Castel, P., Dylus, D., Dzygiel, P., Bradley, K. A. (2024). A novel antibiotic class targeting the lipopolysaccharide transporter. Nature, 625(7995), 566–571. https://doi.org/10.1038/s41586-023-06873-0
Lipsky, M. S., & Sharp, L. K. (2001). From idea to market: the drug approval process. The Journal of the American Board of Family Practice, 14(5), 362-367. PMID: 11572541
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista de divulgación científica iBIO
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los derechos de las publicaciones les pertenecen a los autores. Se permite el autoarchivo o deposito de los trabajos en su versi´ón post-publicación (versión editorial) en cualquier repositorio personal, institucional o temático, redes sociales o científicas. Lo anterior aplica desde el momento de la publicación del artículo en cuestión en la página web de la Revista de divulgación científica iBIO.
